Inflammation/Immunology

COX-2-IN-1 is potent and slective COX-2 inhibitor with an IC₅₀ of 3.9 μM.

D18024 is a phthalazinonderivat antiallergic and antihistaminic activity.

p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.

Cicloxilic acid is a biologically active agent.

Phen-DC3 is a bisquinolinium G-quadruplex (G4) ligand. Phen-DC3 selectively binds to and stabilizes the hybrid quadruplex-duplex hybrid (QDH) derived from the PIM1 promoter. Phen-DC3 also binds to the c-myc promoter Pu24T G4 via extensive π-stacking, and induces polymerase stalling at α-synuclein DNA and RNA G4 sequences. Phen-DC3 Trifluoromethanesulfonate (HY-15594A) downregulates LPS (HY-D1056)-induced TNFRSF21, RIPK3 and p-MLKL in VECs, and ameliorates CLP-induced pulmonary vascular leakage in septic rats. Phen-DC3 can be used in studies related to neurodegenerative diseases and sepsis-associated vascular injury.

Prednisolone farnesylate (PNF21) is a new transdermal corticosteroid with anti-inflammatory activity.

Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor with a K_i of 3.5 nM for binding to RORγt. VTP-43742 blocks Th17 cell differentiation and reduces IL-17A production by inhibiting RORγt-mediated transcriptional activity, thereby suppressing the RORγt/Th17/IL-17 inflammatory axis. VTP-43742 can be used for research on autoimmune diseases and inflammation-related diseases.

Asthma relating compound 1 is an anti-asthmatic agent candidate extracted from patent EP0295656A1.

COX-2-IN-2 is a selective and inducible COX2 inhibitor with an IC₅₀ of 0.24 μM. COX-2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.

Histatin 5 inhibits the activity of the host matrix metalloproteinases MMP-2 and MMP-9 with IC₅₀s of 0.57 and 0.25 μM, respectively.

NCX1022 is an NO-releasing derivative of Hydrocortisone, which is the most widely used anti-inflammatory agent for the treatment of skin inflammation.

Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.

CMI-392 (LDP-392) is an orally active dual 5-lipoxygenase inhibitor and platelet-activating factor receptor (PAFR) antagonist, with an IC₅₀ of 10 nM for human PAF receptor and an IC₅₀ of 100 nM for rat 5-lipoxygenase. CMI-392 blocks PAF receptor binding, inhibits leukotriene synthesis, attenuates PAF-induced hemoconcentration, and suppresses arachidonic acid- and TPA-induced ear swelling in mice. CMI-392 reduces inflammatory cell infiltration, decreases MPO levels, alleviates ocular inflammation, and improves dextran sulfate sodium-induced colitis. CMI-392 can be used in the research of inflammatory and immune-related diseases such as colitis and atopic dermatitis.

S1PR-MO-1 is the modulator of sphingosine-1-phosphate receptor, used for research of hyperproliferative, inflammatory diseases.

Embramine is a monoethanolamine used as an antihistamine and anticholinergic.

LTB4-IN-1 (Compound 6) is a leukotriene synthesis (LTB4) inhibitor with an IC₅₀ of 70 nM.

Anti-inflammatory agent 1 is an anti-inflammatory agent extracted from patent WO 2009003229 A1, example 36.

Antiulcer Agent 1 is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new agent development.

FRG-8701 is a new Histamine H₂-receptor antagonist with an IC₅₀ of ranging from 0.25 to 0.43 μM.

LY210073 is a Leukotriene B₄ (LTB₄) receptor antagonist with an IC₅₀ of 6.2 nM.